A Phase I, Single-center, Open-label, Single-dose Study to Evaluate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of Orally Administered SUVN-G3031 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2017
At a glance
- Drugs SUVN G3031 (Primary)
- Indications Cognition disorders
- Focus Pharmacokinetics
- Sponsors Suven Life Sciences
- 21 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Sep 2017.
- 21 Sep 2017 Status changed from recruiting to completed.
- 29 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Oct 2017.